(NASDAQ: AVTX) Avalo Therapeutics's forecast annual revenue growth rate of -24.54% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Avalo Therapeutics's revenue in 2024 is $2,250,000.On average, 1 Wall Street analysts forecast AVTX's revenue for 2024 to be $961,912, with the lowest AVTX revenue forecast at $961,912, and the highest AVTX revenue forecast at $961,912. On average, 1 Wall Street analysts forecast AVTX's revenue for 2025 to be $801,593, with the lowest AVTX revenue forecast at $801,593, and the highest AVTX revenue forecast at $801,593.
In 2026, AVTX is forecast to generate $801,593 in revenue, with the lowest revenue forecast at $801,593 and the highest revenue forecast at $801,593.